Toxoplasmosis Research Center, School of Medicine, Communicable Diseases Institute, Iranian National Registry Center for Lophomoniasis and Toxoplasmosis, Mazandaran University of Medical Sciences, Km 18, Farah-Abad Road, PO Box 48471-91971, Sari, Iran.
Pulmonary and Critical Care Division, Imam Khomeini Hospital, Iranian National Registry Center for Lophomoniasis (INRCL), Mazandaran University of Medical Sciences, PO Box 48166-33131, Sari, Iran.
Acta Parasitol. 2022 Mar;67(1):535-538. doi: 10.1007/s11686-021-00468-3. Epub 2021 Oct 22.
Lophomoniasis is caused by Lophomonas spp., a new emerging protozoan, which commonly affects the human lower respiratory tract. The Lophomonas parasite mostly lives commensally in the hindgut of cockroaches.
We present the case of a 33-year-old woman, 30 weeks pregnant, who had severe COVID-19. She was intubated upon admission and began the routine COVID-19 treatment. To rule out possible super infection dual with COVID-19, microscopic examination of the patient's mini-bronchoalveolar lavage (mini-BAL) specimen, revealed L. blattarum, which was identified by the SSU rRNA-PCR and sequencing approaches (accession number: MZ093069). According to that, the patient was treated successfully with metronidazole.
To prevent serious complications, lophomoniasis should be listed in co-morbidity cases of COVID-19 infection during the COVID-19 pandemic worldwide. To the best of our knowledge, this is the first co-infection of Lophomonas blattarum and COVID-19 in the world which has been confirmed using a molecular approach.
滴虫病是由滴虫属引起的,一种新出现的原生动物,通常影响人类下呼吸道。滴虫寄生虫主要共生在蟑螂的后肠中。
我们介绍了一位 33 岁的妇女的病例,她怀孕 30 周,患有严重的 COVID-19。她入院时被插管,并开始接受常规 COVID-19 治疗。为了排除可能与 COVID-19 双重感染的超级感染,对患者微型支气管肺泡灌洗(mini-BAL)标本进行了显微镜检查,发现了 Lophomonas blattarum,通过 SSU rRNA-PCR 和测序方法(注册号:MZ093069)进行鉴定。根据这一点,患者成功地用甲硝唑进行了治疗。
为了预防严重的并发症,在全球 COVID-19 大流行期间,应将滴虫病列入 COVID-19 感染的合并症病例中。据我们所知,这是首例使用分子方法确认的 Lophomonas blattarum 和 COVID-19 的合并感染。